Ramosetron versus ondansetron in the prevention of chemotherapy-induced gastrointestinal side effects: A prospective randomized controlled study
Ramosetron versus ondansetron in the prevention of chemotherapy-induced gastrointestinal side effects: A prospective randomized controlled study
复制标题
雷莫司琼与昂丹司琼预防化疗引起的胃肠道副作用：一项前瞻性随机对照研究
DOI：
10.1159/000098418
复制
发表时间：
2007-01-01
期刊：
影响因子：
3.3
通讯作者：
Han, Xiaohong
中科院分区：
文献类型：
--
作者：
Shi, Yuankai;He, Xiaohui;Han, Xiaohong
工作背景：本研究观察并比较雷莫司琼和昂丹司琼对含顺铂化疗所致胃肠道副反应的预防作用。研究方法：采用前瞻性交叉对照研究方法，将50例首次化疗的恶性肿瘤患者随机分为雷莫司琼0.3mg组和昂丹司琼16 mg组。结果：47例患者的治疗效果和50例不良反应进行了分析。两种药物在第1天化疗引起的胃肠道副作用、呕吐和食欲不振方面显示出相似的结果，但到第5天，雷莫司琼在控制食欲不振方面明显优于昂丹司琼。从第3 - 5天，雷莫司琼的止吐作用往往比昂丹司琼更有效。两种药物的头痛、疲劳和便秘发生率相同。结论：雷莫司琼是一种长效、安全的止吐药。版权所有（c）2007 S. Karger AG，巴塞尔
Background: This study observed and compared the preventive effects of ramosetron and ondansetron on gastrointestinal side effects caused by cisplatin-containing chemotherapy. Methods: Fifty patients with malignant tumors undergoing their first chemotherapy were randomly divided into two groups, and each group received 0.3 mg of ramosetron and 16 mg of ondansetron in a prospective crossover comparison study. Results: Data were collected for analysis of the therapeutic effect in 47 cases and for adverse events in 50 cases. Both drugs showed similar results in regard to chemotherapy-induced gastrointestinal side effects, emesis and appetite loss on day 1, but by day 5, ramosetron was significantly better than ondansetron in terms of controlling appetite loss. From days 3 - 5, ramosetron tended to be more effective than ondansetron in its antiemetic action. The incidence of headache, fatigue and constipation was the same for both drugs. Conclusions: Ramosetron is a long-lasting and safe antiemetic agent. Copyright (c) 2007 S. Karger AG, Basel